Targeted drug combo for relapsed DLBCL
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of targeted antibody drugs (polatuzumab vedotin and rituximab) plus two chemo drugs (gemcitabine and oxaliplatin) for people with DLBCL whose cancer returned after their first treatment and who cannot have a stem cell transplant. The goal is to see if this combination works better as a second-line treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- Your doctor says you cannot have a stem cell transplant.
- You have diffuse large B-cell lymphoma (a type of lymphoma) that has come back or not responded to your first treatment.
- You have at least one tumor that can be measured on a scan.
- Your liver, kidneys, and blood counts are working well enough (your doctor can check this).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if adding another drug (X) to a standard chemotherapy mix (Pola-RCHP) works better for people with untreated diffuse large B-cell lymphoma (DLBCL). It is for those whose cancer DNA levels did not drop enough after the first round of treatment.
This trial tests a combination of two targeted drugs, polatuzumab vedotin and glofitamab, for people with large B-cell lymphoma that came back or didn't go away after their first standard treatment. The goal is to see if this combination can help control the lymphoma.
This trial tests a new combination of drugs (Pola-ZR2P) for people with a type of lymphoma called diffuse large B-cell lymphoma (DLBCL) who have not had chemotherapy yet. It aims to see if this treatment is safe and effective.
This trial tests a combination of three drugs (pola, Rituxan, and lenalidomide) for older adults (70+) with a common type of lymphoma (DLBCL) who are not well enough for standard chemotherapy. The goal is to see if this gentler treatment works well for patients who are less fit.
This trial tests whether adding an extra targeted drug (called X) to the standard chemo (Pola-R-CHP) can help people with aggressive B-cell lymphoma that didn't respond well after the first round. It aims to improve outcomes for those who need a stronger treatment approach.
This trial tests different combinations of targeted drugs and chemotherapy for people newly diagnosed with a type of lymphoma called DLBCL. It aims to find which combination is more effective and safer.
Hear when a new Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.